placebo of vildagliptin

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Congestive Heart FailureType 2 Diabetes MellitusType II Diabetes Mellitus

Phase 4

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

CompletedNCT00894868

Novartis PharmaceuticalsCongestive Heart Failure, Type II Diabetes Mellitus

Start: 2009-05-31End: 2012-08-31Updated: 2020-12-17

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

CompletedNCT01528254

Novartis PharmaceuticalsType 2 Diabetes Mellitus

Start: 2012-03-30End: 2019-04-04Updated: 2020-09-24

Related Papers

Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study

Diabetology & Metabolic Syndrome2021-06-151 citations

Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes.

2020-09-2519 citations

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

2019-09-18224 citations

Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.

2017-10-11106 citations